BerGenBio ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
BerGenBio ASA (BRRGF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.551x
Based on the latest financial reports, BerGenBio ASA (BRRGF) has a cash flow conversion efficiency ratio of -0.551x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.95 Million) by net assets ($67.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BerGenBio ASA - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how BerGenBio ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BerGenBio ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BerGenBio ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harbin Sayyas Windows Co. Ltd. A
SHE:301227
|
N/A |
|
Imperial Metals Corporation
PINK:IPMLF
|
0.096x |
|
Aic Mines Ltd
AU:A1M
|
0.175x |
|
FERRO SA ZY 1
F:0MN
|
N/A |
|
Yanpai Filtration Technology Co.Ltd.
SHE:301081
|
N/A |
|
St.Shine Optical Co Ltd
TWO:1565
|
0.005x |
|
Cardinal Ethanol LLC
OTCGREY:CRDE
|
-0.079x |
|
APAC Opto Electronics
TWO:4908
|
0.007x |
Annual Cash Flow Conversion Efficiency for BerGenBio ASA (2014–2024)
The table below shows the annual cash flow conversion efficiency of BerGenBio ASA from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $122.70 Million | $-153.24 Million | -1.249x | +29.27% |
| 2023-12-31 | $127.48 Million | $-225.10 Million | -1.766x | +45.78% |
| 2022-12-31 | $88.50 Million | $-288.23 Million | -3.257x | -312.75% |
| 2021-12-31 | $384.43 Million | $-303.34 Million | -0.789x | -125.73% |
| 2020-12-31 | $670.23 Million | $-234.29 Million | -0.350x | +58.28% |
| 2019-12-31 | $219.75 Million | $-184.15 Million | -0.838x | -51.38% |
| 2018-12-31 | $337.28 Million | $-186.71 Million | -0.554x | -15.37% |
| 2017-12-31 | $350.35 Million | $-168.11 Million | -0.480x | +40.84% |
| 2016-12-31 | $153.27 Million | $-124.31 Million | -0.811x | +16.51% |
| 2015-12-31 | $64.75 Million | $-62.90 Million | -0.972x | -129.87% |
| 2014-12-31 | $127.09 Million | $-53.72 Million | -0.423x | -- |